Clinical Trial Update: Olmesartan Medoxomil in Atherosclerosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for olmesartan medoxomil in essential hypertension and atherosclerotic cardiovascular disease; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Essential Hypertension

Drugs mentioned

• BENICAR (OLMESARTAN MEDOXOMIL)

Snippet

Sponsor: Sankyo Pharma Gmbh | Conditions: Essential Hypertension, Atherosclerotic Cardiovascular Disease | Phase 3 | Status: COMPLETED